
PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.
Founded in 1998, PTC Therapeutics, Inc. is a US-based pharmaceutical company dedicated to developing orally administered, small-molecule drugs targeting genetic disorders, oncology, and infectious diseases. The company's core mission is to discover and commercialize innovative treatments that address unmet medical needs, improving the quality of life for patients worldwide. PTC Therapeutics focuses on creating therapies that are both effective and accessible, aiming to transform the landscape of rare disease treatment.
Notable figures affiliated with PTC Therapeutics include Stuart W. Peltz, a co-founder and key leader in the company's strategic direction. The company has attracted significant investment from prominent venture capital firms and institutional investors. Key achievements include the development and approval of several groundbreaking therapies, such as Translarna for Duchenne muscular dystrophy. PTC Therapeutics' impact is evident in its contributions to advancing medical science and providing hope to patients with rare and challenging conditions.

Amicus Therapeutics
amicusrx.com

Sarepta Therapeutics
sarepta.com

BioCryst Pharmaceuticals
biocryst.com

United Therapeutics

Astria Therapeutics
astriatx.com

Ultragenyx Pharmaceutical
ultragenyx.com

Pliant Therapeutics
pliantrx.com

Ionis Pharmaceuticals
ionispharma.com

Theravance Biopharma
theravance.com

Harmony Biosciences

Intercept Pharmaceuticals

Triplet Therapeutics
triplettx.com

TG Therapeutics
tgtherapeutics.com

SpringWorks Therapeutics
springworkstx.com
Vertex Pharmaceuticals
vrtx.com
Companies similar to PTC Therapeutics include Amicus Therapeutics, Sarepta Therapeutics, BioCryst Pharmaceuticals and United Therapeutics.
PTC Therapeutics was founded in 1998.
PTC Therapeutics' headquarters is located in South Plainfield, NJ, US.
PTC Therapeutics' most recent funding round was for $1B (USD) in October 2022.
As of Oct 27, 2022, PTC Therapeutics has raised a total of $1.6B (USD).
PTC Therapeutics has 1,402 employees as of Feb 6, 2024.